Back to results
US 12,576,135 B2Granted
Compositions and methods for anti-TnMUC1 gold CAR t-cells
AssigneeChimera Bioengineering, Inc.
InventorsBenjamin Wang, Gusti Zeiner, Albert Gacerez, Eytan Herzig
Life of this patent
Estimating the term…
Abstract
Methods and compositions for delivering a payload at TnMUC1 positive cancer cells. Anti-TnMUC1 CARs and transgene payloads can be engineered into immune cells so that the transgene payload is expressed and delivered at desired times from the immune cell. Such anti-TnMUC1 CAR T-cells with transgene payloads can be combined with the administration of other molecules, e.g., other therapeutics such as anticancer therapies.
Claims17
A method for treating a pancreatic cancer, a prostate cancer, or a triple negative, breast cancer, comprising the steps of:
- a) obtaining a primary T-cell comprising a heterologous nucleic acid encoding:
- i) an anti-TnMUC1 chimeric antigen receptor, and
- ii) an IL-12 payload,
- wherein said heterologous nucleic acid is selected from the group consisting of SEQ ID NO:5, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14;
- and
- b) administering the primary T-cell to a subject diagnosed with the pancreatic cancer, the prostate cancer, or the triple negative, breast cancer,
- thereby treating the pancreatic cancer, the prostate cancer, or the triple negative, breast cancer.
4 more elements
Dependencies are inferred from the claim text.